Sclerotherapy of testicular hydroceles with 3% aqueous phenol.
With the evolution of minimally invasive approaches in medicine, phenol has regained its popularity for the sclerotherapy of testicular hydroceles. Together with reported efficiency and safety of 2.5% phenol in the literature, the recently proved safety of 3% phenol in esophageal variceal sclerotherapy has led us to perform a prospective study to lessen the number of sessions. Sclerotherapy with 3% aqueous phenol was applied on an ambulatory basis to 23 patients with 31 hydroceles, who were over 40 years old and who had no fertility problems. The over-all cure rate was 96% with an average follow-up of 3 years, and 58% of the hydroceles required only one session of treatment. The average number of treatment sessions was 2.2 (range; 1-7). One patient with a history of herniorraphy 10 years earlier, was treated surgically following failure of seven sclerotherapy sessions. Phenol, a sclerosant superior to other conventional agents including tetracyclines, requires neither anesthetics nor prophylactic antibiotics. Our findings indicate that sclerotherapy with 3% phenol is an effective, economical and safe form of therapy for patients with hydrocele.
Ozdemir
E
E
Department of Urology, Ankara Numune Hospital, Turkey.
D000328:Adult; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000008:administration & dosage*; D011446:Prospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D015911:Sclerotherapy / Q000379:methods*; D013733:Testicular Diseases / Q000628:therapy*; D006848:Testicular Hydrocele / Q000628:therapy*; D016896:Treatment Outcome
D010636:Phenols; D012597:Sclerosing Solutions